Evidence map›Paper›PMID 40652240›Full record

Observational studyCritical care (London, England)2025

Assessing FilmArray Pneumonia+ panel dynamics during antibiotic treatment to predict clinical success in ICU patients with ventilated hospital-acquired pneumonia and ventilator-associated pneumonia: a multicenter prospective study.

Julien Dessajan, Michaël Thy, Marc Doman, Jules Stern, Antoine Gallet, Gaëlle Fouque, Samuel Chosidow, Stéphane Ruckly, Signara Gueye, Fariza Lamara and 19 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  5. Observational
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Julien DessajanMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France. julien.dessajan@aphp.fr.
Michaël ThyMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Marc DomanMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Jules SternDepartment of Anesthesiology and Critical Care Medicine, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Antoine GalletDepartment of Anesthesiology and Critical Care, Paris Cité University- Beaujon University Hospital, Assistance Publique - Hôpitaux de Paris, Clichy, France.
Gaëlle FouqueDepartment of Anesthesiology and Critical Care Medicine, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Samuel ChosidowDepartment of Anesthesiology and Critical Care, Paris Cité University- Beaujon University Hospital, Assistance Publique - Hôpitaux de Paris, Clichy, France.
Stéphane RucklyDepartment of Biostatistics, OUTCOME REA Research Network, Drancy, France.
Signara GueyeDepartment of Bacteriology, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Fariza LamaraMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Mariem DlelaMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Hermann Do RegoMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Michaël EjzenbergMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Luc HaudebourgMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Julien Le MarecMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Cyril PotierMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Valentine BertiUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France, 75018.
Nathalie GrallUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France, 75018.
Stéphane LoUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France, 75018.
Naouale MaataouiUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France, 75018.
Emilie RondinaudUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France, 75018.
Etienne RuppéUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France, 75018.
Frédéric BertDepartment of Bacteriology, Paris Cité University- Beaujon University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Véronique Leflon-GuiboutDepartment of Bacteriology, Paris Cité University- Beaujon University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Lila BouadmaMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Romain SonnevilleMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Etienne de MontmollinMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.
Laurence Armand-LefèvreUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France, 75018.
Jean-François TimsitMedical and Infectious Diseases ICU, Paris Cité University- Bichat University Hospital, Assistance Publique - Hôpitaux de Paris, 46 Rue Henri Huchard, Paris, 75018, France.

Funding

bioMérieux n°IPM 20586
6 · The paper itself

Abstract

backgroundAccurate microbiological documentation seems central for managing severe pneumonia. While the FilmArray

methodsWe conducted a prospective observational study across four ICUs from April 2022 to June 2024, including patients with ventilator-associated pneumonia (VAP) or ventilated hospital-acquired pneumonia (vHAP). Bacterial loads were monitored on days 0, 1, 3, 7 and 10 and 3 days after stopping antibiotics, using endotracheal aspirates (ETAs) analyzed by FA-PP and standard cultures. The main objective was to assess the correlation between quantitative changes in FA-PP results and clinical success. Quantitative changes over time were analyzed using mixed ordinal logistic regression.

resultsOf the 93 patients enrolled, 60.2% (n = 56) achieved clinical success, while the ICU mortality rate was 25.8% (n = 24). Although FA-PP and culture quantification results declined over time (p < 0.0001), neither method consistently correlated with clinical success (non-significant for both). At diagnosis, FA-PP showed excellent diagnostic performance compared to culture, with a sensitivity of 94% [95% CI: 87-97] and a specificity of 98% [95% CI: 97-98]. Quantitative concordance improved with higher DNA copies, from 22.9% at the culture threshold at 10⁴ DNA copies/ml in FA-PP to 100% at ≥ 10⁷ DNA copies/ml. Diagnostic performance remained stable during antibiotic treatment with 94% sensitivity and 95% specificity in follow-up ETAs.

conclusionsFA-PP provides rapid and accurate diagnostics, but repeated testing did not predict clinical outcomes during treatment, however our small sample size limited the study power.

Indexed as

Anti-Bacterial AgentsHealthcare-Associated PneumoniaPneumonia, Ventilator-AssociatedAgedFemaleHumansIntensive Care UnitsMaleMiddle AgedProspective StudiesTreatment OutcomeAnti-Bacterial AgentsFilmArray pneumonia panelMicrobiological outcomesMultiplex PCRNosocomial pneumoniaVentilator-associated pneumonia

Identifiers

PMID40652240
PMCPMC12255975

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.